Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790075 · ClinicalTrials.gov registry record · Phase 4
Liquid Risperidone in the Treatment of Acute Agitation in Psychiatrically Hospitalized Children
A Phase 4 study, sponsored by Stony Brook University.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT00790075: Completed Phase 4 study, sponsored by Stony Brook University.
NCT00790075 is a Phase 4 study that has completed, run by Stony Brook University. The registered enrollment target is 24 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00790075, a Phase 4 study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
The goal of this study is to demonstrate safety and efficacy of liquid risperidone in psychiatrically hospitalized children, ages 4-12, who would be put in seclusion or restraint, or given an intramuscular injection of diphenhydramine because of their out-of-control behavior if not medicated with risperidone. The first part of the study will: 1) develop appropriate oral doses of medication to reduce out of control or agitated behavior effectively with the fewest side effects, and 2) develop a rating system to measure the children's behavior i.e. level of improvement, sedation, and untoward effects.
Interventions
- DRUG risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2003-01 |
| Est. Completion | 2004-12 |
| Phase | Phase 4 |
What the finished NCT00790075 record still lists
NCT00790075 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which risperidone is the first listed.
NCT00790075 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00790075 about?
NCT00790075 is a clinical study titled "Liquid Risperidone in the Treatment of Acute Agitation in Psychiatrically Hospitalized Children". The goal of this study is to demonstrate safety and efficacy of liquid risperidone in psychiatrically hospitalized children, ages 4-12, who would be put in seclusion or restraint, or given an intramuscular injection of diphenhydramine because of their out-of-control behavior if not medicated with ri...
What is the current status of trial NCT00790075?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2003-01. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00790075?
The interventions under investigation include: risperidone (DRUG).
Who is sponsoring clinical trial NCT00790075?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00790075's enrollment target sits among peer trials
24 1699th of 2000 higher than 276 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia